Los Angeles Capital Management LLC reduced its stake in Mustang Bio, Inc. (NASDAQ:MBIO) by 4.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 92,376 shares of the company’s stock after selling 4,110 shares during the period. Los Angeles Capital Management LLC’s holdings in Mustang Bio were worth $350,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in the stock. Virtu Financial LLC raised its position in shares of Mustang Bio by 465.5% in the 4th quarter. Virtu Financial LLC now owns 187,616 shares of the company’s stock valued at $710,000 after purchasing an additional 154,438 shares during the last quarter. Principal Financial Group Inc. purchased a new position in shares of Mustang Bio in the 4th quarter valued at approximately $48,000. Jane Street Group LLC purchased a new position in shares of Mustang Bio in the 4th quarter valued at approximately $282,000. Squarepoint Ops LLC raised its position in shares of Mustang Bio by 116.3% in the 4th quarter. Squarepoint Ops LLC now owns 253,876 shares of the company’s stock valued at $961,000 after purchasing an additional 136,494 shares during the last quarter. Finally, Nuveen Asset Management LLC raised its position in shares of Mustang Bio by 488.8% in the 4th quarter. Nuveen Asset Management LLC now owns 858,676 shares of the company’s stock valued at $3,251,000 after purchasing an additional 712,834 shares during the last quarter. 25.75% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:MBIO opened at $3.02 on Wednesday. The company has a 50 day moving average price of $3.31 and a 200-day moving average price of $3.56. Mustang Bio, Inc. has a 1-year low of $2.42 and a 1-year high of $5.22. The firm has a market cap of $257.23 million, a price-to-earnings ratio of -2.42 and a beta of 1.85.

Mustang Bio (NASDAQ:MBIO) last released its quarterly earnings results on Tuesday, March 23rd. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.11). As a group, equities research analysts forecast that Mustang Bio, Inc. will post -1.01 EPS for the current year.

In other news, CEO Manuel Md Litchman bought 165,562 shares of the stock in a transaction dated Friday, March 5th. The shares were acquired at an average cost of $3.12 per share, with a total value of $516,553.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 3.39% of the company’s stock.

Several brokerages recently commented on MBIO. Zacks Investment Research lowered shares of Mustang Bio from a “buy” rating to a “hold” rating in a research report on Monday, April 12th. B. Riley reissued a “buy” rating and set a $13.00 price target on shares of Mustang Bio in a research report on Wednesday, December 23rd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Mustang Bio presently has a consensus rating of “Buy” and a consensus price target of $9.25.

Mustang Bio Profile

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Further Reading: Most Active Stocks: Dollar Volume vs Share Volume

Want to see what other hedge funds are holding MBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mustang Bio, Inc. (NASDAQ:MBIO).

Institutional Ownership by Quarter for Mustang Bio (NASDAQ:MBIO)

Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.